UVA Sunscreen with Invisicare Available For International Licensing
LAS VEGAS, July 29 /CNW/ -- Skinvisible, Inc. (OTC Bulletin Board:
SKVI)(http://www.skinvisible.com, http://www.invisicare.com), the developers
of Invisicare, a patented polymer delivery system that enhances topical
skincare products, announces the successful development of a new broad
spectrum sunscreen combining the active ingredient avobenzone (Parsol(R) 1789)
with Invisicare. Avobenzone is one of only two UVA (320-400 nm) sunscreens
approved in the USA. It is on the FDA's Category I sunscreen list, as it
offers broad-range UVA protection and helps protect the skin against the
harmful effects of sun which can cause skin cancers and premature skin aging.
"The results of the studies for our SPF 30 and 50 sunscreens are very
impressive," said James Roszell, PhD for Skinvisible Pharmaceuticals.
"Avobenzone is notoriously unstable when exposed to light with most products
only offering two to four hours of protection. Skinvisible's sunscreens with
Invisicare achieved eight hours of photostability with minimal degradation.
Additionally, Invisicare has the ability to hold ingredients like avobenzone
on the skin for extended periods of time, while resisting wash-off and
perspiration; rating our sunscreen formulas as "very water-resistant".
"The completions of our studies are timely as the FDA reviews new
labeling standards," said Mr. Terry Howlett, President and CEO of Skinvisible.
"The FDA proposed changes to sunscreen labeling so that consumers can easily
identify which sunscreen products offer UVA and UVB protection and at what
level. This four-star ranking of UVA protection levels ranges from "low,"
"medium," "high" to "highest". We foresee that Skinvisible's new broad
spectrum sunscreen would achieve the "highest" rating."
In addition to sunscreens, Skinvisible has a portfolio of 25 topical
dermatology products formulated with Invisicare available for world-wide
licensing. In addition to developing proprietary products for clients,
Skinvisible's formulations include prescription, over-the-counter and cosmetic
products for the treatment of acne, atopic dermatitis, fungal infections, as
well as anti-inflammatories, analgesics, hand sanitizers, anti-aging, and
sunless tanning products.
Parsol(R) 1789 -- registered trademark of DSM Nutritional Products.
About Invisicare(R) -- Invisicare is Skinvisible's patented polymer
delivery system that offers "life-cycle management" and unique enhancements
for topically delivered products. It is a combination of hydrophilic and
hydrophobic polymers that hold active ingredients on the skin for extended
periods of time resisting both wash-off and perspiration. Invisicare controls
the release of actives, reducing irritation and eliminating some costly
manufacturing processes. It is non-occlusive and allows for normal skin
respiration while protecting against environmental irritants.
About Skinvisible Pharmaceuticals, Inc. -- Skinvisible Pharmaceuticals is
a research-and-development company whose primary business objective is to
license its proprietary formulations with Invisicare(R) to pharmaceutical and
cosmeceutical companies as well as assisting companies in revitalizing or
enhancing their existing skin care products. Skinvisible receives a
combination of research and development, license, and royalties fees for the
life of the Invisicare patent. http://www.skinvisible.com
This press release contains 'forward looking' statements within the
meaning of Section 21A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended, and are subject to the
safe harbors created thereby. Such statements involve certain risks and
uncertainties associated with an emerging company. Actual results could differ
materially from those projected in the forward looking statements as a result
of risk factors discussed in Skinvisible, Inc. reports on file with the U.S.
Securities and Exchange Commission (including, but not limited to, a report on
Form 10Q for the quarter ending March 30, 2008)
Doreen McMorran, VP Business Development
Skinvisible Pharmaceuticals, Inc
For further information:
For further information: Doreen McMorran, VP Business Development of
Skinvisible Pharmaceuticals, Inc, +1-702-433-7154, email@example.com Web
Site: http://www.skinvisible.com http://www.invisicare.com